Paper41346702
The efficacy of oligonucleotide-based gene therapeutics in gene silencing.
Patra C and 10 others. Theranostics, 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. The efficacy of oligonucleotide-based gene therapeutics in gene silencing. Papers, record 41346702. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41346702
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Genetic Therapy | Major topic |
| Gene Silencing | Major topic |
| Oligonucleotides, Antisense | Major topic |
| Oligonucleotides | Major topic |
| Humans | |
| RNA, Small Interfering | |
| Animals |
Source PubMed
References229
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20461061 | Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. | Mol Ther | 2010 | https://conductscience.org/library/papers/20461061 | PubMed |
| 2 | 32356888 | Phosphorothioate modified oligonucleotide-protein interactions. | Nucleic Acids Res | 2020 | https://conductscience.org/library/papers/32356888 | PubMed |
| 3 | 24549300 | A Kinetic Model Explains Why Shorter and Less Affine Enzyme-recruiting Oligonucleotides Can Be More Potent. | Mol Ther Nucleic Acids | 2014 | https://conductscience.org/library/papers/24549300 | PubMed |
| 4 | 37111328 | Insights into Exosome Transport through the Blood-Brain Barrier and the Potential Therapeutical Applications in Brain Diseases. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37111328 | PubMed |
| 5 | 38413492 | Eplontersen: First Approval. | Drugs | 2024 | https://conductscience.org/library/papers/38413492 | PubMed |
| 6 | 33636127 | In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs. | Cell | 2021 | https://conductscience.org/library/papers/33636127 | PubMed |
| 7 | 22190188 | Deoxyribozymes and bioinformatics: complementary tools to investigate axon regeneration. | Cell Tissue Res | 2012 | https://conductscience.org/library/papers/22190188 | PubMed |
| 8 | 38609360 | Engineered, nucleocytoplasmic shuttling Cas13d enables highly efficient cytosolic RNA targeting. | Cell Discov | 2024 | https://conductscience.org/library/papers/38609360 | PubMed |
| 9 | 36922504 | Engineered exosomes from different sources for cancer-targeted therapy. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/36922504 | PubMed |
| 10 | 28488596 | The impact of microfluidic mixing of triblock micelleplexes on in vitro / in vivo gene silencing and intracellular trafficking. | Nanotechnology | 2017 | https://conductscience.org/library/papers/28488596 | PubMed |
| 11 | 30846846 | Secondary structure of the segment 5 genomic RNA of influenza A virus and its application for designing antisense oligonucleotides. | Sci Rep | 2019 | https://conductscience.org/library/papers/30846846 | PubMed |
| 12 | 33963053 | Targeting the Conserved Stem Loop 2 Motif in the SARS-CoV-2 Genome. | J Virol | 2021 | https://conductscience.org/library/papers/33963053 | PubMed |
| 13 | 31951854 | Chemical Diversity of Locked Nucleic Acid-Modified Antisense Oligonucleotides Allows Optimization of Pharmaceutical Properties. | Mol Ther Nucleic Acids | 2020 | https://conductscience.org/library/papers/31951854 | PubMed |
| 14 | 35221289 | Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs. | Drug Metab Dispos | 2022 | https://conductscience.org/library/papers/35221289 | PubMed |
| 15 | 31036929 | Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. | Nat Biotechnol | 2019 | https://conductscience.org/library/papers/31036929 | PubMed |
| 16 | 25614280 | Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. | Arterioscler Thromb Vasc Biol | 2015 | https://conductscience.org/library/papers/25614280 | PubMed |
| 17 | 38055260 | Tominersen in Adults with Manifest Huntington's Disease. | N Engl J Med | 2023 | https://conductscience.org/library/papers/38055260 | PubMed |
| 18 | 31863714 | Impact of Phosphorothioate Chirality on Double-Stranded siRNAs: A Systematic Evaluation of Stereopure siRNA Designs. | Chembiochem | 2020 | https://conductscience.org/library/papers/31863714 | PubMed |
| 19 | 31156715 | The Potential for microRNA Therapeutics and Clinical Research. | Front Genet | 2019 | https://conductscience.org/library/papers/31156715 | PubMed |
| 20 | 27001893 | Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. | J Control Release | 2016 | https://conductscience.org/library/papers/27001893 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42673315 | Tripled-Stranded Antisense Oligonucleotide for Biomarker-Activated Suppression of Essential Genes. | Chembiochem | 2026 | https://conductscience.org/library/papers/42673315 | PubMed |
| 42666414 | Combined Targeted Drug Delivery Systems for Mineral Metabolism Disorders in Chronic Kidney Disease: A Narrative Review. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42666414 | PubMed |
| 41752461 | Gold Nanoparticle-Based Precision Medicine Strategies for Glioblastoma: Current Biomedical Applications and Future Outlook. | Molecules | 2026 | https://conductscience.org/library/papers/41752461 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41346702
GET https://conductscience.org/api/papers/v1/41346702/references?page=2